Company Performance - Kanghong Pharmaceutical reported a revenue of approximately 3.624 billion yuan for the first three quarters of 2025, representing a year-on-year increase of 6.23% [1] - The net profit attributable to shareholders of the listed company was about 1.033 billion yuan, showing a year-on-year growth of 6.08% [1] - Basic earnings per share reached 1.12 yuan, which is a year-on-year increase of 5.66% [1] Market Context - As of the report, Kanghong Pharmaceutical has a market capitalization of 29.9 billion yuan [1]

Financial Performance - The company's revenue for Q3 2025 reached ¥1,170,203,783.10, representing a 4.75% increase year-over-year[5] - Net profit attributable to shareholders was ¥303,207,431.06, up 7.71% compared to the same period last year[5] - The basic earnings per share for the period was ¥0.33, which is a 6.45% increase year-over-year[5] - Total operating revenue for the current period reached ¥3,623,865,721.06, an increase of 6.2% compared to ¥3,411,293,193.61 in the previous period[22] - Net profit for the current period was ¥1,021,124,394.93, representing a growth of 5.8% from ¥964,889,830.03 in the previous period[23] - Earnings per share (EPS) for the current period was ¥1.12, compared to ¥1.06 in the previous period, indicating an increase of 5.7%[23] Assets and Liabilities - The total assets at the end of the reporting period amounted to ¥9,870,033,859.62, reflecting a 5.65% increase from the end of the previous year[5] - Total assets increased to ¥9,870,033,859.62 from ¥9,341,936,339.67, marking a growth of 5.7%[21] - Total liabilities rose to ¥719,980,060.47, up from ¥695,069,259.77, reflecting an increase of 3.7%[21] - The total equity attributable to shareholders of the parent company was ¥9,166,361,019.00, compared to ¥8,653,202,130.15, an increase of 5.9%[21] Cash Flow - The net cash flow from operating activities for the year-to-date was ¥1,408,275,688.02, an increase of 12.26%[5] - Operating cash flow for the current period was ¥1,408,275,688.02, an increase of 12.2% compared to ¥1,254,467,611.62 in the previous period[24] - Cash inflow from sales of goods and services was ¥3,867,965,865.99, compared to ¥3,649,309,553.09 in the previous period, reflecting a growth of 6.0%[24] - Total cash outflow from operating activities was ¥2,578,063,329.64, an increase from ¥2,430,058,668.41 in the previous period[24] - Cash flow from financing activities resulted in a net outflow of -¥519,112,267.76, compared to -¥343,198,374.48 in the previous period[25] Investments and Financial Activities - Investment income from financial products was recorded at ¥11,533,310.23, classified as regular income due to its frequency and relevance to business operations[10] - The company reported a financial income of ¥41,612,234.52, down from ¥47,008,183.20, a decline of 11.4%[22] - The company reported a significant increase of 269.90% in prepayments, totaling ¥42,378,031.18[12] - Total cash inflow from investment activities was ¥3,252,470,799.99, up from ¥2,132,043,970.54 in the previous period, representing a 52.5% increase[24] - Net cash flow from investment activities was -¥2,732,633,098.12, worsening from -¥2,316,936,761.18 in the previous period[24] Shareholder Information - Total number of common shareholders at the end of the reporting period is 23,995[15] - Chengdu Kanghong Technology Industry (Group) Co., Ltd. holds 31.70% of shares, totaling 292,014,900 shares[15] - The top ten shareholders include Chengdu Kanghong Technology Industry (Group) Co., Ltd. and several individual shareholders, with no participation in margin trading reported[16] Research and Development - Research and development expenses for the current period were ¥334,157,560.21, slightly down from ¥342,158,088.75, a decrease of 2.4%[22] - The company received a drug registration certificate for Lifi Shite eye drops from the National Medical Products Administration[17] - The company’s subsidiary received clinical trial approval for KH813 injection from the National Medical Products Administration[17] - The company completed the absorption merger of its wholly-owned subsidiary Sichuan Jishengtang Pharmaceutical Co., Ltd.[17] Current Assets and Cash Management - The company reported a total current assets of ¥7,023,154,380.28, an increase from ¥6,288,819,404.18 at the beginning of the period[19] - Cash and cash equivalents decreased to ¥3,828,071,098.77 from ¥5,689,515,722.69[19] - The ending balance of cash and cash equivalents was ¥3,781,405,973.18, an increase from ¥3,263,580,439.45 in the previous period[25] - The company’s cash and cash equivalents decreased by ¥1,844,021,273.38 during the period, compared to a decrease of ¥1,406,413,781.15 in the previous period[25]

二、监事会会议审议情况 证券代码：002773 证券简称：康弘药业 公告编号：2025-058 成都康弘药业集团股份有限公司 第八届监事会第十三次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 成都康弘药业集团股份有限公司（以下简称"公司"）第八届监 事会第十三次会议于 2025 年 10 月 28 日在公司会议室以现场和通讯 相结合的方式召开。会议通知于 2025 年 10 月 23 日以书面、传真或 电子邮件等形式向所有监事发出。本次监事会应到监事 3 名，实到监 事 3 名（其中：监事程砚梅女士以通讯方式参加），会议由监事会主 席龚文贤主持，公司董事会秘书列席会议。本次会议的召开符合《中 华人民共和国公司法》和《成都康弘药业集团股份有限公司章程》的 有关规定。 会议以书面记名投票方式通过了如下决议： 1、会议以3票同意，0票反对，0票弃权审议通过了《2025年第三 季度报告》。 经审核，监事会认为：董事会编制和审核的公司《2025年第三季 1 / 3 度报告》的程序符合法律、行政法规和中国证监会的规定，报告内容 真实 ...

证券代码：002773 证券简称：康弘药业 公告编号：2025-057 成都康弘药业集团股份有限公司 第八届董事会第十三次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 成都康弘药业集团股份有限公司（以下简称"公司"）第八届董 事会第十三次会议于2025年10月28日在公司会议室通过现场和通讯 相结合的方式召开。会议通知已于2025年10月23日以书面、传真或电 子邮件等形式向所有董事发出。本次董事会应到董事九名，实到董事 九名（其中：董事王霖先生、独立董事周德敏先生、邓宏光先生、许 楠女士以通讯方式参加），会议由董事长柯尊洪先生主持，公司监事、 董事会秘书及高级管理人员列席了会议。本次会议的召开符合《中华 人民共和国公司法》（以下简称"《公司法》"）和《成都康弘药业 集团股份有限公司章程》（以下简称"《公司章程》"）的有关规定。 二、董事会会议审议情况 会议以书面记名投票方式表决通过了如下决议： 1. 会议以9票赞成、0票反对、0票弃权审议通过了《2025年第三 季度报告》。 《2025 年第三季度报告》于 2025 年 ...

证券代码：002773 证券简称：康弘药业 公告编号：2025-060 成都康弘药业集团股份有限公司 1、2022 年股票增值权激励计划第三个行权期行权条件达成，本 次可行权的激励对象总计 1 人，可申请行权的股票增值权数量为 18 万份，占截至2025年9月30日公司总股本921,320,954股的0.0195%。 2、本次行权对公司总股本数量无影响，对公司基本每股收益及 净资产收益率影响较小，具体影响以经会计师事务所审计的数据为准， 本次股票增值权行权不会对公司财务状态和经营成果产生重大影响。 成都康弘药业集团股份有限公司（以下简称"公司"）于 2025 年 10 月 28 日召开第八届董事会第十三次会议、第八届监事会第十三 次会议，审议通过了《关于 2022 年股票增值权激励计划第三个行权 期行权条件达成的议案》，根据公司《2022 年股票增值权激励计划(草 案）》，本次 2022 年股票增值权激励计划第三个行权期为自首次授 予日起36个月后的首个交易日起至首次授予日起48个月内的最后一 1 / 11 个交易日当日止，即本次 2022 年股票增值权激励计划第三个行权期 为 2025 年 8 月 30 日 ...

证券代码：002773 证券简称：康弘药业 公告编号：2025-056 成都康弘药业集团股份有限公司 关于注销部分募集资金专用账户的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 一、募集资金基本情况 1、首次公开发行股票募集资金基本情况 经中国证券监督管理委员会（以下简称"中国证监会"）"证监 许可[2015]1198号文"核准，成都康弘药业集团股份有限公司（以下 简称 "公司"）公开发行人民币普通股股票4,560.00万股，每股发 行价为13.62元，扣除证券公司承销费、保荐费等费用后实际募集资 金净额为人民币57,624.77万元。上述募集资金已于2015年6月23日全 部到位，经信永中和会计师事务所（特殊普通合伙）审验，并出具了 XYZH/2015CDA50084号《验资报告》。 2、公开发行可转换公司债券募集资金基本情况 经中国证监会（证监许可[2019]2572号）核准，公司公开发行了 1,630.00万张可转换公司债券，每张面值100元，发行总额163,000.00 万元，扣除证券公司承销费、保荐费等费用后实际募集资金净额为人 民币160, ...

Core Points - Kanghong Pharmaceutical (002773) reported that as of October 20, 2025, the number of shareholders is 24,892 [1]

Core Viewpoint - Kanghong Pharmaceutical's stock has experienced a significant increase of 70.42% year-to-date, but has recently faced declines of 7.11% over the past five trading days, 17.82% over the past twenty days, and 20.81% over the past sixty days [1] Financial Performance - For the first half of 2025, Kanghong Pharmaceutical reported a revenue of 2.454 billion yuan, representing a year-on-year growth of 6.95%, and a net profit attributable to shareholders of 730 million yuan, which is a 5.41% increase compared to the previous year [2] Shareholder Information - As of October 10, 2025, the number of shareholders for Kanghong Pharmaceutical increased to 24,000, with an average of 28,565 circulating shares per person, a slight decrease of 0.20% [2] - The company has distributed a total of 2.038 billion yuan in dividends since its A-share listing, with 1.04 billion yuan distributed over the last three years [3] Stockholder Composition - As of June 30, 2025, the fourth largest circulating shareholder is Hong Kong Central Clearing Limited, holding 27.275 million shares, a decrease of 5.316 million shares from the previous period [3] - Other notable shareholders include Dachen Rui Xiang Mixed A and Dachen Competitive Advantage Mixed A, with varying changes in their holdings [3] Business Overview - Kanghong Pharmaceutical, established on October 3, 1996, and listed on June 26, 2015, is primarily engaged in the research, production, and sales of chemical drugs, traditional Chinese medicine, and biological products [1] - The revenue composition of the company includes 54.83% from biological drugs, 32.49% from traditional Chinese medicine, and 12.50% from chemical drugs [1]

Core Viewpoint - Kanghong Pharmaceutical's stock has experienced a significant increase of 71.58% year-to-date, but has recently seen declines of 6.48% over the past five trading days, 17.72% over the past twenty days, and 20.12% over the past sixty days [1] Financial Performance - For the first half of 2025, Kanghong Pharmaceutical reported revenue of 2.454 billion yuan, representing a year-on-year growth of 6.95%, and a net profit attributable to shareholders of 730 million yuan, which is a 5.41% increase compared to the previous year [2] Shareholder Information - As of October 10, 2025, the number of shareholders for Kanghong Pharmaceutical is 24,000, an increase of 0.20% from the previous period, with an average of 28,565 circulating shares per shareholder, a decrease of 0.20% [2] - The company has distributed a total of 2.038 billion yuan in dividends since its A-share listing, with 1.04 billion yuan distributed over the last three years [3] Stockholder Composition - As of June 30, 2025, the largest circulating shareholder is Hong Kong Central Clearing Limited, holding 27.275 million shares, a decrease of 5.316 million shares from the previous period [3] - Other notable shareholders include Dachen Rui Xiang Mixed A and Dachen Competitive Advantage Mixed A, with varying changes in their holdings [3] Business Overview - Kanghong Pharmaceutical, established on October 3, 1996, and listed on June 26, 2015, is primarily engaged in the research, production, and sales of chemical drugs, traditional Chinese medicine, and biological products [1] - The revenue composition of the company includes 54.83% from biological drugs, 32.49% from traditional Chinese medicine, and 12.50% from chemical drugs [1]

Core Insights - The article highlights the significant performance of certain funds in the third quarter, particularly the "Yongying Technology Smart Selection" fund, which achieved a remarkable 194% increase, making it the top-performing fund of the year [1][2] - The report indicates a substantial growth in fund size, with "Yongying Technology Smart Selection" increasing from 1.166 billion to 11.521 billion yuan, nearly a ninefold increase in a single quarter [2] - The article also discusses the ongoing optimism in the innovative pharmaceutical sector, with funds like "Great Wall Pharmaceutical Industry Selection" showing over 100% growth [1][4] Fund Performance - "Yongying Technology Smart Selection" fund's top holdings include leading optical module stocks such as "Yizhongtian" (Xinyi Sheng, 300502), Zhongji Xuchuang (300308), and Tianfu Communication (300394), which significantly contributed to its net value [2] - The fund's share count surged from 700 million to 3.466 billion, resulting in a profit of 4.715 billion yuan for investors in the third quarter [2] - The "Great Wall Pharmaceutical Industry Selection" fund also saw its size grow from 1.132 billion to 1.790 billion yuan, with a share increase from 678 million to 932 million [5] Sector Insights - The global cloud computing industry remains a focal point, with AI model valuations increasing and a notable 100% quarter-on-quarter growth in token numbers [3] - The innovative pharmaceutical sector continues to attract attention, with funds maintaining high stock positions despite recent market adjustments [6][8] - The article suggests that the technology and pharmaceutical sectors may still have upward potential, although careful stock selection is advised [8] Future Outlook - The article indicates that the technology sector, particularly AI and cloud computing, is expected to see increased investment, with potential for new opportunities in the industry chain [9] - The innovative pharmaceutical sector is projected to strengthen its global competitiveness, supported by upcoming industry conferences and positive data trends [8] - The article emphasizes the importance of not solely relying on past performance to predict future outcomes in the cloud computing sector, highlighting the need for caution [9]